Mixed Hormone Receptor (ER+/PR- Or ER-/PR+) Breast Cancer

$ 4.99

4.6 (74) In stock

Detailed information on mixed hormone receptor (ER+/PR- or ER-/PR+) breast cancer prognosis, based on the latest scientific studies.

Solving a breast cancer mystery – why do 'double-positive' women do better? - Cancer Research UK - Cancer News

The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB)

Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor

Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells - ScienceDirect

Heterogeneity in hormone-dependent breast cancer and therapy: Steroid hormones, HER2, melanoma antigens, and cannabinoid receptors - ScienceDirect

Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer

An overview on Estrogen receptors signaling and its ligands in breast cancer - ScienceDirect

Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer - Modern Pathology

An emerging generation of endocrine therapies in breast cancer: a clinical perspective

Endocrine and Cell Surface Receptor Signaling in Breast Carcinogenesis